| |
NewswireToday - /newswire/ -
Pittsburgh, PA, United States, 06/30/2008 - Dr. Jeffrey Cohen and Dr. John Maier of ChemImage recently attended an invitation only meeting of the National Cancer Institute to discuss Issues in Clinical Prostate Cancer.
|
| |
Dr. Cohen and Dr. Maier have been recognized for their expertise in oncology and imaging and were able to provide a valuable contribution to identifying new opportunities for incorporating imaging modalities into strategies for treatment and management of prostate cancer.
Dr. Cohen spoke on the use of Raman Molecular Imaging (RMI) as a potential method, which can provide additional information to pathologists and oncologists about the pathophysiology of a particular tissue. Specifically, Dr. Cohen presented a summary of recent work using Raman Molecular Imaging in the setting of prostate cancer, which was performed in collaboration with researchers from The Mayo Clinic. This information can potentially influence clinical management because it relates eventual clinical outcomes to objective measurements, which can be made on a biopsy specimen.
Dr. Jeffrey K. Cohen MD is President of the Triangle Urological Group in Pittsburgh, PA, and also serves as Director of the Division of Urology at Allegheny General Hospital and associate professor of surgery at Drexel University/Allegheny General Hospital. Dr. Cohen sits on the ChemImage Board of Directors and plays a significant role in the direction of the company’s biomedical research. Dr. Cohen is best known in the Urology community for his significant contributions in bringing cryosurgery to the operating room. Continuing in his effort to bring prostate cancer patients better treatments in the clinic, Dr. Cohen has long been a supporter of Molecular Imaging research.
Dr. John Maier PhD MD serves as ChemImage’s Vice President of Biomedical Research. He noted, “The work presented to the NCI is an aspect of the Digital Pathology Initiative ChemImage has aimed at improving the quality and quantity of information which can be used to make clinical decisions.” Dr. Maier joined the ChemImage Corporation in 2002 as a Senior Biomedical Scientist and is the operational leader of the biomedical applications group. Prior to his time at ChemImage, Dr. Maier was a resident at UPMC Shadyside where he matriculated after completing his MD and PhD in Physics at the University of Illinois. Dr. Maier’s focus is developing applications of ChemImage technology, which will ultimately impact clinical medicine.
About ChemImage
ChemImage Corporation is a world leader in Chemical Imaging technologies providing instrumentation, software and expert consulting to government, industrial and academic organizations. ChemImage offers these products and services for a range of applications in various fields including defense, security, pharmaceuticals, forensics and biomedical diagnostic research. Our state-of-the-art Chemical Imaging technology can help to reveal critical chemical and biological information about processes, products and services.
ChemImage’s main headquarters is in Pittsburgh, Pennsylvania and houses research and development laboratories as well as engineering and manufacturing facilities.
|
vogtt[.]chemimage.com 
